Research Topics
| Robert J KindersSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activityRobert J Kinders
Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, Science Applications International Corporation Frederick, Inc, NationalCancer Institute Frederick, Frederick, MD 21702, USA
Clin Cancer Res 16:5447-57. 2010..A quantitative pharmacodynamic immunofluorescence assay for γH2AX was developed, validated, and tested in human tumor xenograft models with the use of clinically relevant procedures...- Advances in using PARP inhibitors to treat cancerShivaani Kummar
Division of Cancer Treatment and Diagnosis, 31 Center Drive, National Cancer Institute, Bethesda, MD 20892, USA
BMC Med 10:25. 2012.... - Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenograftsRobert J Kinders
Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, Science Applications International Corporation Frederick, Inc, National Cancer Institute Frederick, Frederick, MD 21702, USA
Clin Cancer Res 14:6877-85. 2008..S. Food and Drug Administration's Exploratory Investigational New Drug Application. Performance of the study design, needle biopsy procedure, and validated pharmacodynamic assay were evaluated in human tumor xenograft models... - Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cellsLihua H Wang
Laboratory of Human Toxicology and Pharmacology, Science Applications International Corporation, Frederick, MD, USA
Clin Cancer Res 16:1073-84. 2010..Here, we describe an assay that directly examines changes in levels of the nuclear DNA damage marker gammaH2AX in individual CTCs of patients treated with chemotherapeutic agents... - Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibitionAnnamaria Rapisarda
SAIC Frederick Inc, National Cancer Institue at Frederick, Frederick, MD 21702, USA
Mol Cancer Ther 8:1867-77. 2009..These results strongly suggest that combination of anti-vascular endothelial growth factor antibodies with HIF-1 inhibitors is an attractive therapeutic strategy targeting in the hypoxic tumor microenvironment... - Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissuesThomas D Pfister
Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, SAIC Frederick, Inc, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America
PLoS ONE 7:e50494. 2012..Cellular response to Top1 inhibitors is complex, but Top1 target engagement is a necessary first step in this process. This paper reports the development and validation of a quantitative immunoassay for Top1 in tumors... - Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivityThomas D Pfister
Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, Science Applications International Corporation Frederick Inc, National Cancer Institute Frederick, Frederick, MD 21702, USA
Mol Cancer Ther 8:1878-84. 2009....